Introduction {#s001}
============

Rheumatoid arthritis (RA) is a systemic autoimmune disease (Churov *et al.*, [@B5]). Methotrexate (MTX) is a disease-modifying antirheumatic drug (DMARD) and the most commonly used first-line agent for the treatment of RA (Aslibekyan *et al.*, [@B3]). The pharmacological action of MTX is the inhibition of the enzyme dihydrofolate reductase (DHFR), which interferes with DNA replication and cell proliferation (Jekic *et al.*, [@B11]; Sramek *et al.*, [@B21]). Several factors influence the response to MTX, including genetic factors (Berkani *et al.*, [@B4]) such as micro-RNAs (miRNAs). miRNAs are small noncoding single chain RNAs that are ∼22 nucleotides in length and can regulate the expression of genes by degrading messenger RNA (mRNA) or repressing mRNA translation (Akhtar *et al.*, [@B1]). The miRNA-24 regulates the development of adult hematopoietic progenitor cells (Roy *et al.*, [@B19]). miRNA-24 requires base complementarity to bind to *DHFR* to regulate its expression.

A single nucleotide polymorphism (SNP) in the miRNA gene or the 3′ untranslated region (3′-UTR) of the target gene could create, destroy, or modify the miRNA binding site and influence resistance or sensitivity to treatment or expression of a target gene by interfering with miRNA function (Passetti *et al.*, [@B18]; Song *et al.*, [@B20]). The *DHFR* −829C-T polymorphism is located in the 3′-UTR of the gene on chromosome 5q14. The miRNA-24 sequences lie 14 bp downstream of this region (Murata *et al.*, [@B15]). In the absence of miRNA-24 binding to the *DHFR* gene, DHFR is overexpressed and MTX resistance can occur (Mishra *et al.*, [@B14]).

A change in the sequence of the gene coding for miRNA-24 could counteract the effects of the wild or polymorphic variant of the *DHFR* gene and may be linked to MTX response by RA patients. The aim of this study was to evaluate the *DHFR* −829C-T polymorphism, plasma DHFR concentrations, the *miRNA-24* gene sequence, and the association with the response to MTX treatment in Mexican RA patients.

Materials and Methods {#s002}
=====================

Study subjects {#s003}
--------------

This case--control study included 135 patients treated at an outpatient clinic between August 2015 and December 2016. Inclusion criteria were women, Mexican, ≥18 years old, RA diagnosed according to the American College of Rheumatology (Arnett *et al.*, [@B2]), and oral MTX treatment (5--20 mg per week) for at least 1 year before initiation of the study. We excluded patients who were being treated with leflunomide or biological DMARDs, as well as patients who had incomplete clinical data and women who stopped MTX treatment.

The patients were classified into two groups, responders and nonresponders, based on their response to MTX according to the disease activity score (DAS28) (Dhaon *et al.*, [@B6]). The responder group comprised 73 patients having a DAS28 score ≤3.2, and the nonresponder group had 62 patients who had a DAS28 score \>3.2.

Clinical and laboratory evaluations {#s004}
-----------------------------------

All patients were evaluated according to sociodemographic and clinical characteristics, and blood samples were collected from all 135 study participants. The plasma samples were subsequently used for quantification of DHFR enzyme levels using the human dihydrofolate reductase enzyme-linked immunosorbent assay (ELISA) Kit (MyBioSource, Inc., San Diego, CA). The erythrocyte sedimentation rate (ESR) of the samples was determined by the Westergren method and levels of C-reactive protein (CRP) and anticitrullinated protein antibodies (ACPAs) were determined by nephelometry and ELISA, respectively. Genomic DNA was extracted from the remaining sample using the modified Miller technique (Miller *et al.*, [@B13]).

DHFR −829C-T genotyping {#s005}
-----------------------

The −829C-T polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) using the following primers: forward, 5′-CTTCTCCAAGACCCCAACTG-3′ and reverse, 5′-CTTCCAGGTTGTTTTCAATTTTT-3′ (Gómez-Gómez *et al.*, [@B8]). The PCR amplification product (269 bp) was digested with 5 U of the *Tsp*RI enzyme (New England Biolabs, Beverly, MA). The digested products were analyzed on 8% polyacrylamide gels (29:1) stained with silver nitrate. We obtained 203, 45, and 21 bp fragments for the CC genotype, 248, 203, 45, and 21 bp fragments for the CT genotype, and 248 and 21 bp fragments for the TT genotype.

Identification of miRNA-24 gene sequence {#s006}
----------------------------------------

Amplification of the *miRNA-24* gene was performed by endpoint PCR. The following primers were designed and used to amplify a 519 bp fragment from chromosome 9 that contains the *miRNA-24* gene: forward, 5′-CGCGGTGAACTCTCTCTTGT-3′ and reverse, 5′-CACGCACCCACTCTAACTGT-3′. Sanger sequencing was performed using an ABI 3730XL instrument (Applied Biosystems, Foster City, CA). The miRNA-24 gene sequence was analyzed using the Sequencher 5.4.6 program (Gene Codes Corporation, Ann Arbor, MI).

Statistical analysis {#s007}
--------------------

Quantitative variables are presented as means and standard deviations. The qualitative variables are expressed as frequencies and percentages. The analysis was based on nonparametric statistics. The allelic frequencies and genotypic distribution of the polymorphisms were compared between the study groups by the chi-squared and Mann--Whitney *U* tests. Statistical analyses were carried out using the SPSS statistical package, v. 21 (Chicago, IL). *p* \< 0.05 was considered significant.

Ethics {#s008}
------

This study was approved by the Research Committee of the participating center (R-2015-1301-68). All study participants voluntarily provided written informed consent.

Results {#s009}
=======

Clinical and laboratory characteristics {#s010}
---------------------------------------

The sociodemographic characteristics were determined for the responders and nonresponders ([Table 1](#T1){ref-type="table"}). The mean MTX dose received by the responders and nonresponders was similar at 11.8 ± 4.9 and 11.4 ± 3.6 mg per week, respectively. ESR values also showed no statistically significant difference between the two groups. Meanwhile, CRP values were nearly twofold higher for nonresponders than responders (13.2 ± 14 vs. 7.1 ± 7.2 mg/mL) and this difference was statistically significant (*p* = 0.014). The rate of corticosteroid use was also significantly higher for nonresponders than responders (69.4% vs. 42.5%; *p* = 0.003).

###### 

Characteristics of Responders and Nonresponders to Methotrexate Treatment

                                             *Responders*   *Nonresponders*   p*-Value*
  ------------------------------------------ -------------- ----------------- -----------
  Demographics                                                                
   Age (years), mean ± SD                    57 ± 12        55 ± 10           0.93
   Smoker, *n* (%)                           4 (5.5)        7 (11.3)          0.36
   Family history, *n* (%)                   37 (50.7)      30 (48.4)         0.93
  Disease characteristics                                                     
   ESR (mm/h), mean ± SD                     23.2 ± 10      27.8 ± 13         0.56
   CRP (mg/mL), mean ± SD                    7.1 ± 7.2      13.2 ± 14         **0.014**
   ACPAs, no. of positive/no. of total (%)   40/58 (69.0)   30/54 (55.6)      0.20
  Treatment                                                                   
   MTX dosage (mg), mean ± SD                11.8 ± 4.9     11.4 ± 3.6        0.29

                    n *(%)*     n *(%)*      
  ----------------- ----------- ----------- -----------
  NSAIDs            64 (87.7)   55 (88.7)   1.00
  Sulfasalazine     39 (53.4)   30 (48.4)   0.68
  Corticosteroids   31 (42.5)   43 (69.4)   **0.003**
  Chloroquine       17 (23.3)   17 (27.4)   0.72

  Genotypic distribution   n *(%)*     n *(%)*      
  ------------------------ ----------- ----------- ------
    CC                     27 (37.0)   21 (33.9)   0.88
    CT                     38 (52.1)   35 (56.4)   
    TT                     8 (10.9)    6 (9.7)     

  Allelic frequency   n *(%)*     n *(%)*      
  ------------------- ----------- ----------- ------
    C                 92 (63.0)   77 (62.1)   0.87
    T                 54 (37.0)   47 (37.9)   

Bold values indicate *p* \< 0.05.

CC: homozygous genotype; CT: heterozygous genotype; TT: homozygous variant genotype.

ACPAs, anticitrullinated protein antibodies; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate (Westergren method); MTX, methotrexate; NSAIDs, nonsteroidal anti-inflammatory drugs; SD, standard deviation.

DHFR −829C-T genotypes {#s011}
----------------------

No differences were found in the distribution of genotypes between the responders and nonresponders ([Table 1](#T1){ref-type="table"}). The predominant genotype in both groups was CT, and the most frequent allele in both groups was C.

Quantification of the DHFR enzyme-genotype-DAS28 {#s012}
------------------------------------------------

Based on the genotype and DAS28 classification, the DHFR enzyme concentration was analyzed for 88 (65%) of the study subjects ([Table 2](#T2){ref-type="table"}). The highest mean DHFR concentration was found for responders carrying the CC genotype (6.8 ng/mL) and in nonresponders carrying the TT genotype (7.4 ng/mL). No significant differences were found when the groups were compared.

###### 

Plasma Levels of the DHFR Enzyme According to *DHFR* −829C-T Genotype

  *Genotype*   *Responders*     *Nonresponders*   p*-Value*
  ------------ ---------------- ----------------- -----------
  CC           6.8 ± 2.7 (21)   6.5 ± 2.0 (11)    0.31
  CT           6.1 ± 2.6 (24)   6.1 ± 3.1 (25)    0.94
  TT           6.5 ± 1.5 (5)    7.4 ± 1.8 (2)     0.72

The values are expressed in ng/mL.

CC: homozygous genotype; CT: heterozygous genotype; TT: homozygous variant genotype.

DHFR, dihydrofolate reductase.

Sequencing of miRNA-24 {#s013}
----------------------

We analyzed the sequence of the 68 bases corresponding to the mature sequence of miRNA-24. Among the 130 samples analyzed, no genetic mutation was found in either chain of the miRNA-24 sequence in the responder or nonresponder group ([Fig. 1](#f1){ref-type="fig"}).

![Electropherograms of the *miRNA-24* gene sequence. **(a)** 5′-3′ chain. **(b)** 3′-5′ chain. Color images are available online.](fig-1){#f1}

Discussion {#s014}
==========

The relationship between MTX response and the *DHFR* −829C-T polymorphism, plasma DHFR concentration, and variants in the *miRNA-24* gene sequence has not been investigated in previous studies. In a 135 patient cohort of Mexican patients with RA, we found no association between these parameters and MTX treatment response. The sociodemographic characteristics were similar among responders and nonresponders to MTX treatment. However, the DAS28 score based on CRP levels was significantly higher in the nonresponders group, as was the rate of corticosteroid use (*p* = 0.003). This finding could be associated with a need of nonresponders for additional medication to reduce pain and inflammation due to the high level of RA activity.

Genotypes {#s015}
---------

The only published study on the *DHFR* −829CT polymorphism in a Mexican population was carried out by Gómez-Gómez *et al.* ([@B8]), who analyzed the response to MTX by children with acute lymphoblastic leukemia. In that study, the authors determined that the Mexican population was in Hardy--Weinberg equilibrium and identified a positive relationship between the T allele and risk of disease relapse due to a lack of response to MTX. They also found that the predominant genotype among responders and nonresponders was CT (63.6% and 81.3%, respectively), which is consistent with the findings for this study. In contrast, Goto *et al.* ([@B9]) reported that for a Japanese population the CC genotype was the most frequent *DHFR* −829C-T genotype. Other studies associated the presence of the T allele with MTX treatment failure (Mishra *et al.*, [@B14]). However, our analysis of minor homozygous genotypes showed no significant difference between responders and nonresponders (10.9% responders vs. 9.7% for nonresponders).

As this study is an exploratory work and no previous information has been described similar to the aim of this research in Mexican patients, we considered the small sample size a limitation with a probably insufficient statistical power to detect small differences between the comparison of allele and genotype frequencies observed in responders and nonresponders to MTX treatment ([Table 1](#T1){ref-type="table"}). However, the sample size allows us to perform this comparison. In addition, we observe that despite an increase in the number of patients, the allelic frequencies are maintained (a minimum of 100 alleles are required).

Level of DHFR enzyme {#s016}
--------------------

Some studies suggested that elevated DHFR levels are related to failure to respond to MTX treatment (O\'Dell *et al.*, [@B17]; Jekic *et al.*, [@B11]). We quantified the DHFR enzyme levels in 88 patients and found no significant difference between the groups. Although DHFR enzyme levels have been analyzed in cancer cell cultures (Mishra *et al.*, [@B14]), to our knowledge our study is the first to analyze the association of DHFR enzyme concentrations in RA patients with *DHFR* −829C-T genotypes. All of our patients had levels more than 6.1 ± 3.1 ng/mL, which suggests that patients with RA have DHFR enzyme overexpression relative to that seen in healthy populations (Naithani *et al.*, [@B16]). Galbiatti *et al.* ([@B7]) found that *DHFR* gene expression levels in cancer cells dose-dependently increased with MTX treatment. This could in part explain why we saw similar elevations in DHFR enzyme levels in both groups, because patients in this study had begun MTX treatment at least 1 year before study initiation.

miRNA-24 {#s017}
--------

Alterations in the miRNA gene region may play an important role in RA pathogenesis or treatment response and may alter miRNA expression and/or maturation (Li *et al.*, [@B12]). Gutierrez-Camino *et al.* ([@B10]) determined that the TT genotype of SNP rs2648841 in the premature sequence of the miR-1208 gene has a protective function in leukemia patients being treated with MTX. Our study is the first to analyze the miRNA-24 gene sequence with respect to RA and showed that there were no differences in the gene sequence between MTX responders and nonresponders.

Conclusion {#s018}
==========

The *DHFR* −829C-T polymorphism is not associated with MTX response by RA patients, and no variations were found in the miRNA-24 gene that could modify the response to MTX treatment or DHFR enzyme levels. Thus, additional studies to examine other polymorphisms in the DHFR pathway are needed to explain the differences in response to MTX treatment by RA patients.
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